PR92 antigen in human prostate fluid: Elevated levels in prostate cancer

B. I. Carlin; J. Marachie; M. F. Venegas; A. J. Schaeffer; N. Shaw; G. M. Hass; A. W. Rademaker; C. Lee; J. T. Grayhack

doi:10.1002/pros.2990250307

PR92 antigen in human prostate fluid: Elevated levels in prostate cancer

B. I. Carlin, J. Marachie, M. F. Venegas, A. J. Schaeffer, N. Shaw, G. M. Hass, A. W. Rademaker, C. Lee^*, J. T. Grayhack

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

In this preliminary study, we report that an enzyme‐linked immunofluorescence assay (EFLA) was developed for the determination of PR92 antigen in prostatic fluid, utilizing anti‐PR92 monoclonal antibody. Fluid samples from 64 patients were assayed. PR92 antigen was expressed as unit per microgram (U/μg) of prostatic fluid proteins. One hundred percent of men (7 out of 7) less than 50 years of age demonstrated concentrations less than 25 U/μg; 91% of men (10 out of 11) with documented carcinoma, and only 9.5% of men (2 out of 21) with benign prostatic hyperplasia, demonstrated concentrations above 230 U/μg. The mean concentration of PR92 antigen in prostatic fluid of a group of patients suspected of having prostate cancer (high‐risk group; 227 ± 42 U/μg) was significantly greater than that of those with benign prostatic hyperplasia (87 ± 23 U/μg; P = 0.05). Further evaluation of this potential marker and of other antigens within the prostatic fluid is warranted. © 1994 Wiley‐Liss, Inc.

Original language	English (US)
Pages (from-to)	156-161
Number of pages	6
Journal	The Prostate
Volume	25
Issue number	3
DOIs	https://doi.org/10.1002/pros.2990250307
State	Published - Sep 1994

Funding

Keywords

benign prostatic hyperplasia
carcinoma
enzyme‐linked immunofluorescence assay (EFLA)

ASJC Scopus subject areas

Urology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pros.2990250307

Cite this

@article{d771a0bd995644e68bb34efe4a43c729,

title = "PR92 antigen in human prostate fluid: Elevated levels in prostate cancer",

abstract = "In this preliminary study, we report that an enzyme‐linked immunofluorescence assay (EFLA) was developed for the determination of PR92 antigen in prostatic fluid, utilizing anti‐PR92 monoclonal antibody. Fluid samples from 64 patients were assayed. PR92 antigen was expressed as unit per microgram (U/μg) of prostatic fluid proteins. One hundred percent of men (7 out of 7) less than 50 years of age demonstrated concentrations less than 25 U/μg; 91% of men (10 out of 11) with documented carcinoma, and only 9.5% of men (2 out of 21) with benign prostatic hyperplasia, demonstrated concentrations above 230 U/μg. The mean concentration of PR92 antigen in prostatic fluid of a group of patients suspected of having prostate cancer (high‐risk group; 227 ± 42 U/μg) was significantly greater than that of those with benign prostatic hyperplasia (87 ± 23 U/μg; P = 0.05). Further evaluation of this potential marker and of other antigens within the prostatic fluid is warranted. {\textcopyright} 1994 Wiley‐Liss, Inc.",

keywords = "benign prostatic hyperplasia, carcinoma, enzyme‐linked immunofluorescence assay (EFLA)",

author = "Carlin, {B. I.} and J. Marachie and Venegas, {M. F.} and Schaeffer, {A. J.} and N. Shaw and Hass, {G. M.} and Rademaker, {A. W.} and C. Lee and Grayhack, {J. T.}",

year = "1994",

month = sep,

doi = "10.1002/pros.2990250307",

language = "English (US)",

volume = "25",

pages = "156--161",

journal = "The Prostate",

issn = "0270-4137",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - PR92 antigen in human prostate fluid

T2 - Elevated levels in prostate cancer

AU - Carlin, B. I.

AU - Marachie, J.

AU - Venegas, M. F.

AU - Schaeffer, A. J.

AU - Shaw, N.

AU - Hass, G. M.

AU - Rademaker, A. W.

AU - Lee, C.

AU - Grayhack, J. T.

PY - 1994/9

Y1 - 1994/9

N2 - In this preliminary study, we report that an enzyme‐linked immunofluorescence assay (EFLA) was developed for the determination of PR92 antigen in prostatic fluid, utilizing anti‐PR92 monoclonal antibody. Fluid samples from 64 patients were assayed. PR92 antigen was expressed as unit per microgram (U/μg) of prostatic fluid proteins. One hundred percent of men (7 out of 7) less than 50 years of age demonstrated concentrations less than 25 U/μg; 91% of men (10 out of 11) with documented carcinoma, and only 9.5% of men (2 out of 21) with benign prostatic hyperplasia, demonstrated concentrations above 230 U/μg. The mean concentration of PR92 antigen in prostatic fluid of a group of patients suspected of having prostate cancer (high‐risk group; 227 ± 42 U/μg) was significantly greater than that of those with benign prostatic hyperplasia (87 ± 23 U/μg; P = 0.05). Further evaluation of this potential marker and of other antigens within the prostatic fluid is warranted. © 1994 Wiley‐Liss, Inc.

AB - In this preliminary study, we report that an enzyme‐linked immunofluorescence assay (EFLA) was developed for the determination of PR92 antigen in prostatic fluid, utilizing anti‐PR92 monoclonal antibody. Fluid samples from 64 patients were assayed. PR92 antigen was expressed as unit per microgram (U/μg) of prostatic fluid proteins. One hundred percent of men (7 out of 7) less than 50 years of age demonstrated concentrations less than 25 U/μg; 91% of men (10 out of 11) with documented carcinoma, and only 9.5% of men (2 out of 21) with benign prostatic hyperplasia, demonstrated concentrations above 230 U/μg. The mean concentration of PR92 antigen in prostatic fluid of a group of patients suspected of having prostate cancer (high‐risk group; 227 ± 42 U/μg) was significantly greater than that of those with benign prostatic hyperplasia (87 ± 23 U/μg; P = 0.05). Further evaluation of this potential marker and of other antigens within the prostatic fluid is warranted. © 1994 Wiley‐Liss, Inc.

KW - benign prostatic hyperplasia

KW - carcinoma

KW - enzyme‐linked immunofluorescence assay (EFLA)

UR - http://www.scopus.com/inward/record.url?scp=0028136319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028136319&partnerID=8YFLogxK

U2 - 10.1002/pros.2990250307

DO - 10.1002/pros.2990250307

M3 - Article

C2 - 7520579

AN - SCOPUS:0028136319

SN - 0270-4137

VL - 25

SP - 156

EP - 161

JO - The Prostate

JF - The Prostate

IS - 3

ER -

PR92 antigen in human prostate fluid: Elevated levels in prostate cancer

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this